Form 4: RAPT Director Ashley Dombkowski Receives RSU Grant

RAPT Therapeutics Director Ashley L. Dombkowski was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Ashley L. Dombkowski, a Director of RAPT Therapeutics, Inc., received an annual grant of 4,956 restricted stock units (RSUs).
• The transaction date for this acquisition was January 30, 2026.
• These RSUs were granted at a price of $0 per unit, representing compensation.
• The RSUs are part of the Issuer's Amended & Restated Non-Employee Director Compensation Policy.
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• The RSUs will fully vest on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, routine governance action. While not a major catalyst, it reflects standard compensation practices and aligns director interests with shareholders, contributing to stable corporate governance.

Positives

• The grant of restricted stock units aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard component of non-employee director compensation, indicating continuity in governance practices.

Future Outlook

The vesting schedule for the restricted stock units indicates a future commitment, with full vesting expected on the first anniversary of the January 30, 2026 grant date.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units, are a common form of compensation for non-employee directors in the biotechnology and pharmaceutical sectors. This practice is designed to align the interests of directors with long-term shareholder value creation, a standard governance approach across the industry.

Comparison to Industry Standards

• The grant of RSUs to a non-employee director is a standard compensation practice, comparable to policies at peer biotech companies such as Moderna (MRNA) or BioNTech (BNTX), which frequently use equity to incentivize and retain board members.
• The vesting schedule, typically one year for annual director grants, is consistent with industry benchmarks for similar roles, ensuring directors have a vested interest in the company's performance over a reasonable period.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially fostering more aligned decision-making.
• Employees: No direct impact on employees is indicated by this director compensation filing.

Next Steps

• The restricted stock units are expected to fully vest on the first anniversary of the grant date, which is January 30, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a non-employee director, which is a standard compensation practice and does not present new information that would significantly alter the investment thesis for RAPT Therapeutics. It reflects ongoing corporate governance but does not provide catalysts for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

RAPT Therapeutics, RAPT, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Ashley Dombkowski